Immunotech Biopharm Ltd

6978

KYG4721A1004

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:13 13/01/2026 pm IST			5-day change	1st Jan Change
2.790 ^HKD	0.00%		-0.71%	-4.78%

09/12	Immunotech Biopharm Purchases 120 Million Yuan Worth of Structured Deposit Products	MT
08/12	Immunotech Biopharm subscribes to structured deposit products from Bank of China worth RMB120 million	RE

Immunotech Biopharm Purchases 120 Million Yuan Worth of Structured Deposit Products

Published on 12/09/2025 at 08:53 am IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Immunotech Biopharm Ltd

09/12	Immunotech Biopharm Purchases 120 Million Yuan Worth of Structured Deposit Products	MT
08/12	Immunotech Biopharm subscribes to structured deposit products from Bank of China worth RMB120 million	RE
16/25/16	Immunotech Biopharm Ltd Announces Board and Audit Committee Changes, Effective October 16, 2025	CI
19/25/19	Immunotech Biopharm says underwriter agreed to underwrite up to 123.1 million rights shares	RE
19/25/19	HKEX says trading in shares of Immunotech Biopharm will be halted on Sept 19	RE
21/25/21	Immunotech Biopharm's H1 Loss Widens; Shares Rise 7%	MT
20/25/20	Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/25/26	Immunotech Biopharm Ltd Announces Board Appointments, Effective 26 June 2025	CI
02/25/02	Immunotech Biopharm CEO/CTO Resigns	MT
30/25/30	Immunotech Biopharm Says Zhang Jian Appointed As Acting CEO	RE
30/25/30	Immunotech Biopharm Ltd Announces Chief Executive Officer Changes	CI
30/25/30	Immunotech Biopharm Ltd Announces the Resignation of Wang Yu as Executive Director and Chief Technology Officer, Effective 25 June 2025	CI
29/25/29	Immunotech Biopharm Ltd Auditor Raises 'Going Concern' Doubt	CI
25/25/25	Immunotech Biopharm Ltd Announces Board and Committee Changes	CI
01/25/01	Immunotech Biopharm's 2024 Loss Narrows	MT
31/25/31	Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2024	CI
31/25/31	Immunotech Biopharm Says Conditional New Drug Application Of EAL Accepted By NMPA	RE
31/25/31	Immunotech Biopharm Ltd. Announces Conditional New Drug Application of EAL	CI
28/25/28	Immunotech Biopharm Ltd. Announces Recent Business Updates	CI
11/24/11	Immunotech's Leukemia Drug Gets Breakthrough Therapy Designation in China	MT
11/24/11	Immunotech Biopharm Ltd Announces CAR-T-19 Injection Receives Breakthrough Therapy Designation	CI
02/24/02	Immunotech Biopharm Ltd Announces Executive Changes	CI
23/24/23	Immunotech Biopharm Ltd(SEHK:6978) dropped from S&P Global BMI Index	CI
23/24/23	Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	CI
29/24/29	Immunotech Biopharm CFO Steps Down	MT

Immunotech Biopharm Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of immune cell products for treatments of cancers. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. It also provides cell cryopreservation services. The Company mainly conducts its businesses in the domestic market.

Employees

173

Sector

Biotechnology & Medical Research

Calendar

20/03 - Q4 2025 Earnings Release (Projected)

More about the company